Free Trial
NASDAQ:ADIL

Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

$1.05
-0.12 (-10.26%)
(As of 07/26/2024 ET)
Today's Range
$1.05
$1.19
50-Day Range
$1.04
$1.55
52-Week Range
$0.77
$8.88
Volume
797,897 shs
Average Volume
4.05 million shs
Market Capitalization
$4.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ADIL stock logo

About Adial Pharmaceuticals Stock (NASDAQ:ADIL)

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

ADIL Stock Price History

ADIL Stock News Headlines

3 Penny Stocks to Watch Now, 7/25/24
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?
Prepare for a Recession Unlike Any Other
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
Prepare for a Recession Unlike Any Other
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
See More Headlines
Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
7/26/2024
Next Earnings (Estimated)
8/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADIL
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-5,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.46 per share

Miscellaneous

Free Float
3,620,000
Market Cap
$4.78 million
Optionable
No Data
Beta
1.31
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Cary John Claiborne MBA (Age 63)
    CEO, President & Director
    Comp: $728.31k
  • Dr. Bankole A. Johnson DSc (Age 64)
    FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer
    Comp: $435k
  • Mr. Joseph A. M. Truluck M.B.A. (Age 46)
    MBA, CFO, Treasurer & Secretary
    Comp: $358.49k
  • Mr. Tony Goodman (Age 60)
    COO & Director
    Comp: $33k
  • Mr. John R. Martin J.D.
    Chief Legal Officer
  • Ms. Catherine Fratila
    Controller

ADIL Stock Analysis - Frequently Asked Questions

How have ADIL shares performed this year?

Adial Pharmaceuticals' stock was trading at $1.86 at the start of the year. Since then, ADIL shares have decreased by 43.5% and is now trading at $1.05.
View the best growth stocks for 2024 here
.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its earnings results on Tuesday, May, 14th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.17.

When did Adial Pharmaceuticals' stock split?

Adial Pharmaceuticals's stock reverse split before market open on Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Adial Pharmaceuticals IPO?

Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

Who are Adial Pharmaceuticals' major shareholders?

Adial Pharmaceuticals' top institutional investors include Concourse Financial Group Securities Inc.. Insiders that own company stock include Kevin Schuyler, James W Jr Newman and William B Stilley III.
View institutional ownership trends
.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM) and Tandem Diabetes Care (TNDM).

This page (NASDAQ:ADIL) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners